Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus

© 2016 Elsevier B.V. Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligo...

Full description

Saved in:
Bibliographic Details
Main Authors: Ingrid A. Beck, Rachel Payant, Nicole Ngo-Giang-Huong, Woottichai Khamduang, Laddawan Laomanit, Gonzague Jourdain, Lisa M. Frenkel
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84962283790&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/55894
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Description
Summary:© 2016 Elsevier B.V. Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (. OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings.